Literature DB >> 24631952

Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.

Lixin Wang1, Sachiko Mogami2, Hiroshi Karasawa3, Chihiro Yamada2, Seiichi Yakabi3, Koji Yakabi4, Tomohisa Hattori2, Yvette Taché3.   

Abstract

We previously reported that ghrelin prevented l-dopa (LD)-induced inhibition of gastric emptying (GE) of a non-nutrient solution in rats. Parkinson's disease treatment involves the combined administration of l-dopa with the enzyme l-amino acid decarboxylase inhibitor, carbidopa (CD) to reduce peripheral formation of dopamine. We investigated the effect LD/CD given orogastrically (og) on GE of a non-nutrient or nutrient meal and whether og pretreatment with rikkunshito, a kampo medicine clinically used to treat gastroparesis, influenced LD/CD effect on GE and postprandial antral and duodenal motility in conscious rats. LD/CD (20/2 mgkg(-1)) decreased significantly GE to 26.3 ± 6.0% compared to 61.2 ± 3.2% in og vehicle monitored 20-min after a non-nutrient meal and to 41.9 ± 5.8% compared to 72.9 ± 5.2% in og vehicle monitored 60 min after a nutrient meal. Rikkunshito (0.5 or 1.0 g kg(-1)) reduced the LD/CD (20/2 mg kg(-1)) inhibition of GE of non-nutrient meal (36.9 ± 7.4% and 46.6 ± 4.8% respectively vs. 12.1 ± 7.4% in og vehicle plus LD/CD) while having no effect alone (56.6 ± 8.5%). The ghrelin antagonist, [d-Lys(3)]-GHRP-6 (1 mg kg(-1)) injected intraperitoneally partially reversed rikkunshito preventive effect on LD/CD-inhibited GE. Rikkunshito (1.0 g kg(-1)) blocked LD/CD (20/2 mg kg(-1))-induced delayed GE of a nutrient meal and the reduction of postprandial antral motility. In 6-hydroxydopamine-induced Parkinson's disease rat model, rikkunshito (1.0 g kg(-1), og) also prevented LD/CD-inhibited gastric emptying of a nutrient meal and enhanced fasting plasma levels of acylated ghrelin. These data indicate that oral rikkunshito alleviates the delayed GE induced by LD/CD in naïve and PD rat model in part through ghrelin-related mechanisms.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gastric motility; Ghrelin; Parkinson's disease; Rats; Rikkunshito; l-dopa

Mesh:

Substances:

Year:  2014        PMID: 24631952      PMCID: PMC5944319          DOI: 10.1016/j.peptides.2014.02.011

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  66 in total

1.  Dietary herb extract rikkunshi-to ameliorates gastroparesis in Parkinson's disease: a pilot study.

Authors:  Hirokazu Doi; Ryuji Sakakibara; Mitsutoshi Sato; Shigekazu Hirai; Tohru Masaka; Masahiko Kishi; Yohei Tsuyusaki; Akihiko Tateno; Fuyuki Tateno; Osamu Takahashi; Tsuyoshi Ogata
Journal:  Eur Neurol       Date:  2014-01-21       Impact factor: 1.710

2.  The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.

Authors:  D R Robertson; N D Wood; H Everest; K Monks; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

3.  Reduced ghrelin production induced anorexia after rat gastric ischemia and reperfusion.

Authors:  Sachiko Mogami; Hidekazu Suzuki; Seiichiro Fukuhara; Juntaro Matsuzaki; Kenji Kangawa; Toshifumi Hibi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-11-23       Impact factor: 4.052

4.  Gastric emptying time and gastric motility in patients with Parkinson's disease.

Authors:  R Hardoff; M Sula; A Tamir; A Soil; A Front; S Badarna; S Honigman; N Giladi
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

5.  Gastrointestinal dysfunction in a Parkinson's disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus.

Authors:  Hong Can Zhu; Jing Zhao; Chang Yue Luo; Qian Qian Li
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

Review 6.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  The herbal medicine Rikkunshi-to stimulates and coordinates the gastric myoelectric activity in post-operative dyspeptic children after gastrointestinal surgery.

Authors:  M Yagi; S Homma; M Kubota; Y Iinuma; S Kanada; Y Kinoshita; M Ohtaki; S Yamazaki; H Murata
Journal:  Pediatr Surg Int       Date:  2004-01-09       Impact factor: 1.827

Review 8.  Actions and therapeutic pathways of ghrelin for gastrointestinal disorders.

Authors:  Michael Camilleri; Athanasios Papathanasopoulos; Suwebatu T Odunsi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06       Impact factor: 46.802

Review 9.  The 6-hydroxydopamine model of Parkinson's disease.

Authors:  Nicola Simola; Micaela Morelli; Anna R Carta
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

10.  Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival.

Authors:  N Fujitsuka; A Asakawa; Y Uezono; K Minami; T Yamaguchi; A Niijima; T Yada; Y Maejima; U Sedbazar; T Sakai; T Hattori; Y Kase; A Inui
Journal:  Transl Psychiatry       Date:  2011-07-26       Impact factor: 6.222

View more
  7 in total

Review 1.  Endoscopic treatment of gastroparesis.

Authors:  Thomas R McCarty; Tarun Rustagi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

2.  Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis.

Authors:  Luca Toti; R Alberto Travagli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-10-02       Impact factor: 4.052

3.  New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  H Karasawa; C Pietra; C Giuliano; S Garcia-Rubio; X Xu; S Yakabi; Y Taché; L Wang
Journal:  Neurogastroenterol Motil       Date:  2014-10-19       Impact factor: 3.598

4.  Patterns of Brain Activation and Meal Reduction Induced by Abdominal Surgery in Mice and Modulation by Rikkunshito.

Authors:  Lixin Wang; Sachiko Mogami; Seiichi Yakabi; Hiroshi Karasawa; Chihiro Yamada; Koji Yakabi; Tomohisa Hattori; Yvette Taché
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

Review 5.  Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome.

Authors:  Naoki Fujitsuka; Yasuhito Uezono
Journal:  Front Pharmacol       Date:  2014-12-10       Impact factor: 5.810

6.  Open Label Trial of the Efficacy and Safety Profile of Rikkunshito used for the Treatment of Gastrointestinal Symptoms in Patients with Parkinson's Disease: A Pilot Study.

Authors:  Koji Yakabi; Naomi Yamaguchi; Shino Ono; Norihito Yoshida; Eriko Hosomi; Kenjiro Hayashi; Mitsuko Ochiai; Kosuke Maezawa; Kyoichi Nomura
Journal:  Curr Ther Res Clin Exp       Date:  2017-07-31

Review 7.  Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto.

Authors:  Toru Kono; Mitsuo Shimada; Masahiro Yamamoto; Atushi Kaneko; Yuji Oomiya; Kunitsugu Kubota; Yoshio Kase; Keiko Lee; Yasuhito Uezono
Journal:  Front Pharmacol       Date:  2015-08-04       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.